Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

26.01.2021 | case report

Sustained remission of adult Langerhans histiocytosis utilizing molecular therapy

verfasst von: Bernhard Doleschal, Ulrich Popper

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Summary

Recent advances in molecular diagnostics classify Langerhans cell histiocytosis as an orphan disease strongly dependent on alterations in MAP kinase pathway, most prominently BRAF V600E mutation. Molecular targeted therapy with vemurafenib often leads to long-term remission. Efforts to expand therapeutic approaches include MEK inhibition or modulation of cellular senescence.
Vorheriger Artikel Autologous stem cell transplantation in light-chain amyloidosis
Nächster Artikel The emerging role of NOTCH target genes in Egyptian childhood acute lymphoblastic leukemia
Literatur
1.
Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379:856–68.CrossRef
2.
Badalian-Very G, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–23.CrossRef
3.
Berres M, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to histiocytosis X? Br J Haematol. 2015;169:3–13.CrossRef
4.
McClain K. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2020;2020(1):395–399.CrossRef
5.
Girschikofsky M, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013;8:72.CrossRef
6.
Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol. 1997;28:9–14.CrossRef
7.
Aricò M. Langerhans cell histiocytosis in adults: more questions than answers? Eur J Cancer. 2004;40:1467–73.CrossRef
8.
Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment. Cancer Sci. 2018;109:3707–13.CrossRef
9.
Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135:1319–31.CrossRef
10.
Christopher Z, Binitie O, Henderson-Jackson E, Perno J, Makanji RJ. Langerhans cell histiocytosis of bone in an adult: a case report. Radiol Case Rep. 2018;13:310–4.CrossRef
11.
Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009;52:97–101.CrossRef
12.
Klein C. Therapieformen der Langerhanszell Histiocytose. 2020. V‑422; DGHO.
13.
Cantu MA, et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7:e43257.CrossRef
14.
15.
Goyal G, et al. The mayo clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc. 2019;94:2054–71.CrossRef
16.
Hyman DM, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36.CrossRef
17.
Diamond EL, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567:521–4.CrossRef
18.
Kobayashi M, et al. BRAF-V600E mutation on circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis. Blood. 2014;124:3209–3209.CrossRef
19.
Donadieu J, et al. Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. 2019;37:2857–65.CrossRef
Metadaten
Titel
Sustained remission of adult Langerhans histiocytosis utilizing molecular therapy
verfasst von
Bernhard Doleschal
Ulrich Popper
Publikationsdatum
26.01.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00684-7

Weitere Artikel der Ausgabe 1/2021

Pharmacokinetic considerations in geriatric cancer patients

  • Open Access
  • short review

Prevalence of comorbidities in elderly cancer patients

  • Open Access
  • short review

Cancer prehabilitation—a short review

  • Open Access
  • short review

Immunoglobulin light chain amyloidosis

  • Open Access
  • short review

ASCO 2020: highlights in breast cancer

  • Open Access
  • short review

Genitourinary cancers—best of ASCO 2020

  • Open Access
  • short review